MTPH Midatech Pharma Plc

TIDMMTPH

Midatech Pharma PLC

16 September 2021

REACH

16 September 2021

Midatech Pharma PLC

("Midatech" or the "Company")

Official Opening of New Cardiff Headquarters

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the formal opening today of its new headquarters, incorporating purpose built laboratory facilities and offices at 1 Caspian Point in Cardiff, UK.

The Company has moved to the 1 Caspian Point building, part of the Parmer Cardiff campus on the city's waterfront, where it has created 8,050 sq ft of offices and laboratories on the ground and first floors. This new headquarters provides bespoke accommodation to facilitate the Company's future plans, particularly with its programmes ustilising its Q-Sphera 3D printing technology to encapsulate medicines in bio-degradable polymers for improved delivery and targeting.

Stephen Stamp, Chief Executive Officer of Midatech, said: "Our technology is unique and patented and we have identified a strategy to work on multiple Q-Sphera programmes simultaneously and partner them at an early stage.

"To execute on that plan Midatech needed expanded, purpose-designed labs, as our previous facilities were far from ideal with labs split over two floors and difficulties moving materials and equipment in and out. The new premises at Caspian Point have achieved this without a material increase in our costs and are modern, 50 per cent larger, and much more usable, with a layout tailored to suit our needs exactly, with capacity for further expansion."

Vaughan Gething MS, Welsh Government Minister for the Economy, when officially opening the new Midatech headquarters said: "Our ambition is for Wales to be a global leader in Life Sciences, whilst stimulating economic growth and creating new high-skilled jobs. We are already able to provide the right environment for companies to innovate and grow and, working alongside the NHS, together we can tackle the greatest healthcare challenges of our generation and address health inequalities. I'm very pleased to see how this business has grown and will play an important part in Wales' expanding Life Sciences sector."

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: +44 (0)29 2048 0180 
 www.midatechpharma.com 
 
 Panmure Gordon (UK) Limited (Nominated Adviser and Joint 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 Tel: +44 (0)20 7886 2500 
 
 Turner Pope Investments (TPI) Limited (Joint Broker) 
 Andrew Thacker / James Pope (Corporate Broking) 
  Tel: +44(0)20 3657 0050 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: +44 (0)20 3934 6630 
 Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Maxwell Colbert 
  Tel: +1 (646) 653 7028 
  Email: mcolbert@edisongroup.com 
 
             About Midatech Pharma PLC 
             Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
             MTP) is a drug delivery technology company focused on improving 
             the bio-delivery and bio-distribution of medicines. The Company 
             combines approved and development medications with its proprietary 
             and innovative drug delivery technologies to provide compelling 
             products that have the potential to powerfully impact the 
             lives of patients. 
             The Company has developed three in-house technology platforms, 
             each with its own unique mechanism to improve delivery of 
             medications to sites of disease. All of the Company's technologies 
             have successfully entered human use in the clinic, providing 
             important validation of the potential for each platform: 
              *    Q-Sphera(TM) platform: a disruptive micro-technology 
                   used for sustained release to prolong and control the 
                   release of therapeutics over an extended period of 
                   time (from weeks to months). 
 
 
              *    MidaSolve(TM) platform: an innovative nanotechnology 
                   used to dissolve insoluble drugs so that they can be 
                   administered in liquid form directly and locally into 
                   tumours. 
 
 
              *    MidaCore(TM) platform: a leading-edge nanotechnology 
                   used for targeting medications to sites of disease. 
 
 
 
             The platform nature of the technologies offers the potential 
             to develop multiple drug assets rather than being reliant 
             on a limited number of programmes. Midatech's technologies 
             are supported by 36 patent families including 120 granted 
             patents and an additional 70 patent applications. Midatech's 
             headquarters and R&D facility is in Cardiff, UK. For more 
             information please visit www.midatechpharma.com 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASFFFIMEFSEDU

(END) Dow Jones Newswires

September 16, 2021 11:59 ET (15:59 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024